HireQuest Reports Third Quarter 2026 Financial Results with Revenue Growth
HireQuest (Nasdaq: HQI) reported its third quarter 2026 financial results, showing a total revenue increase of 4.0% to $8.8 million compared to the prior year. On a pro forma basis, which accounts for the divestiture of MRINetwork assets, total revenue growth was significantly higher at 11.1%. The company noted improving demand in the commercial staffing sector and resilience within its franchise model. Despite revenue gains, net income fell to $1.7 million ($0.12 per diluted share) from $2.3 million in the prior-year period. This decline was primarily driven by a $1.3 million write-down of notes receivable due to a franchised location repossession and higher workers' compensation expenses. Adjusted EBITDA remained stable at $4.5 million, consistent with the third quarter of 2025.
Coverage
- HireQuest Reports Third Quarter 2026 Financial Results with Revenue Growth
- InMode Reports Q3 2026 Financial Results with Stable Revenue and Reaffirmed Outlook
- First International Bank of Israel Reports Q3 2026 Financial Results
- Edible Garden Schedules Q3 2026 Financial Results and Business Update Conference Call
- Archer Aviation Reports Q3 2026 Results with First Powertrain Revenue from Anduril
- Archer Aviation Inc. - 10-Q Filing
- KKR & Co. declares $0.195 dividend
- ContextLogic Reports Q3 2026 GAAP EPS of -$0.29 and Revenue of $32.2 Million
- GS BDC (GSBD) Reports Q3 2026 Financial Results with Decreased NAV and Rising Nonaccruals
- Allogene targets ALPHA3 enrollment completion by year-end 2027 while planning midyear 2027 clinical update
- Barings BDC Reports Q3 2026 Results with Slight NAV and NII Decline
- Lexicon Pharmaceuticals Reports Q3 2026 Financial Results and Clinical Pipeline Updates
- Leapfrog Acquisition Corp - 10-Q Filing
- PROCEPT BioRobotics Corp - 10-Q Filing
- Meridian3 Industrials Acquisition Corp - 10-Q Filing
- uniQure Reports Q3 2026 Financial Results and AMT-130 Clinical Updates
- Nuvectis Pharma Reports Q3 2026 Financial Results and Clinical Pipeline Updates
- Royalty Pharma plc - 10-Q Filing
- UroGen Pharma Ltd. - 8-K Filing
- Nuvectis Pharma, Inc. - 10-Q Filing
- uniQure N.V. - 8-K Filing
- uniQure N.V. - 4 Filing
- FDA Grants Priority Review for uniQure's Huntington's Disease Gene Therapy
- uniQure N.V. - 8-K Filing